Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.39 |
| ▸ | ODC1 | P11926 | 2/20 | 0.33 |
| ▸ | GSR | P00390 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ACACA | Q13085 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 3/20 | 0.31 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.30 |
| ▸ | GABRP | O00591 | 1/20 | 0.30 |
| ▸ | GABRD | O14764 | 1/20 | 0.30 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1518982 | 1.00 | CPB2 (0.39) | CPB2ODC1GSRACACBACACA | |
| SCHEMBL5664168 | 0.82 | CPB2 (0.39) | CPB2ODC1GSRACACBACACA | |
| SCHEMBL5664164 | 0.82 | CPB2 (0.39) | CPB2ODC1GSRACACBACACA | |
| SCHEMBL28562438 | 0.76 | CPB2 (0.42) | CPB2ODC1GSRACACBACACA | |
| SCHEMBL28562441 | 0.76 | CPB2 (0.42) | CPB2ODC1GSRACACBACACA | |
| SCHEMBL27458705 | 0.75 | TSHR (0.42) | ACACBACACATSHR | |
| SCHEMBL15173970 | 0.74 | CPB2 (0.38) | CPB2ODC1GSRLMNABLM | |
| SCHEMBL7278614 | 0.74 | CPB2 (0.38) | CPB2ODC1GSRLMNABLM | |
| SCHEMBL8146401 | 0.69 | TSHR (0.43) | CPB2GSRTSHR | |
| SCHEMBL27913441 | 0.69 | ALDH1A1 (0.36) | ACACBACACATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302964-A1 | Topical Compositions and Methods for Treatment of Diabetic Neuropathies | CROSS III WILLIAM H (US) | 2025-10-02 | — | — | US | claimed |
| US-12329818-B2 | Topical compositions and methods for treatment of diabetic neuropathies | CROSS III WILLIAM H (US) | 2025-06-17 | — | — | US | claimed |
| US-20190285632-A1 | METABALOMICS AND VIRAL DIAGNOSTICS SUITE | EXCISION BIOTHERAPEUTICS, INC. (US) | 2019-09-19 | — | — | US | claimed |
| US-20190275154-A1 | Topical Compositions and Methods for Treatment of Diabetic Neuropathies | CROSS III WILLIAM H (US) | 2019-09-12 | — | — | US | claimed |
| EP-3510148-A1 | HIV CLINICAL PLAN | Excision Biotherapeutics, Inc. (US) | 2019-07-17 | — | — | EP | claimed |
| US-20190194652-A1 | HIV CLINICAL PLAN | EXCISION BIOTHERAPEUTICS, INC. (US) | 2019-06-27 | — | — | US | claimed |
| EP-3465213-A1 | METABALOMICS AND VIRAL DIAGNOSTICS SUITE | Excision Biotherapeutics, Inc. (US) | 2019-04-10 | — | — | EP | claimed |
| WO-2018049372-A1 | HIV CLINICAL PLAN | EXCISION BIOTHERAPEUTICS INC (US) | 2018-03-15 | — | — | WO | claimed |
| WO-2017205460-A1 | METABALOMICS AND VIRAL DIAGNOSTICS SUITE | EXCISION BIOTHERAPEUTICS, INC. (US) | 2017-11-30 | — | — | WO | claimed |
| US-20250302964-A1 | Topical Compositions and Methods for Treatment of Diabetic Neuropathies | CROSS III WILLIAM H (US) | 2025-10-02 | — | — | US | disclosed |
| US-12329818-B2 | Topical compositions and methods for treatment of diabetic neuropathies | CROSS III WILLIAM H (US) | 2025-06-17 | — | — | US | disclosed |
| US-12012634-B2 | Methods for diagnosing, prognosing, and treating parkinson's disease or parkinsonism | POPULATION BIO, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| CN-113793646-B | Spectral image unmixing method based on weighted non-negative matrix factorization and application thereof | 上海交通大学 | 2023-11-28 | — | — | CN | disclosed |
| US-20230020697-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSING, PROGNOSING, AND TREATING NEUROLOGICAL CONDITIONS | POPULATION DIAGNOSTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| WO-2005083089-A1 | GAMMA-BUTYROBETAINE HYDROXYLASE ORIGINATED FROM NEUROSPORA CRASSA | CJ CORPORATION (KR) | 2005-09-09 | — | — | WO | disclosed |
| US-5028538-A | Stereospecific hydration of crotonobetaine | SIGMA TAU INDUSTRIES FARMACEUTICHE RIUNITE S.P.A. (IT) | 1991-07-02 | — | — | US | disclosed |
| EP-0244370-B1 | PROCESS FOR PREPARING GAMMA BUTYROBETAINE | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1990-09-19 | — | — | EP | disclosed |
| US-4806282-A | CATALYTIC HYDROGENATION OF CROTONOYLBETAINE CHLORIDE | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1989-02-21 | — | — | US | disclosed |
| EP-0244370-A2 | Process for preparing gamma butyrobetaine | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1987-11-04 | — | — | EP | disclosed |
| US-4382092-A | Pharmaceutical composition comprising gamma-butyrobetaine for the treatment of syndromes induced by L-carnitine deficiency | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1983-05-03 | — | — | US | disclosed |